Analysts Offer Predictions for Delcath Systems Q1 Earnings

Delcath Systems, Inc. (NASDAQ:DCTH) – HC Wainwright decreased their Q1 2026 earnings estimates for shares of Delcath Systems in a research report issued to clients and investors on Monday, March 2nd. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.01) per share for the quarter, down from their prior forecast of $0.13. HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Delcath Systems’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Delcath Systems’ Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.27) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at $0.10 EPS and FY2028 earnings at $1.13 EPS.

Several other research analysts have also commented on DCTH. BTIG Research decreased their target price on Delcath Systems from $23.00 to $19.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Wall Street Zen downgraded shares of Delcath Systems from a “buy” rating to a “hold” rating in a report on Saturday. Evercore set a $27.00 target price on shares of Delcath Systems in a research note on Thursday, February 26th. Stephens dropped their target price on shares of Delcath Systems from $25.00 to $18.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Delcath Systems in a report on Monday, December 29th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $22.50.

Delcath Systems Stock Down 3.7%

Shares of Delcath Systems stock opened at $8.60 on Wednesday. The business has a 50-day moving average price of $9.93 and a 200 day moving average price of $10.17. Delcath Systems has a fifty-two week low of $8.12 and a fifty-two week high of $18.23. The firm has a market cap of $298.85 million, a P/E ratio of 122.86 and a beta of 0.38.

Delcath Systems (NASDAQ:DCTH) last issued its earnings results on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. The business had revenue of $20.73 million for the quarter, compared to analyst estimates of $20.35 million. Delcath Systems had a net margin of 3.17% and a return on equity of 2.70%.

Institutional Investors Weigh In On Delcath Systems

Several large investors have recently added to or reduced their stakes in DCTH. Rosalind Advisors Inc. boosted its holdings in shares of Delcath Systems by 13.8% during the second quarter. Rosalind Advisors Inc. now owns 3,300,389 shares of the company’s stock valued at $44,885,000 after acquiring an additional 400,000 shares during the period. Vanguard Group Inc. increased its holdings in shares of Delcath Systems by 2.9% in the 3rd quarter. Vanguard Group Inc. now owns 1,657,428 shares of the company’s stock worth $17,817,000 after acquiring an additional 46,693 shares during the period. Geode Capital Management LLC lifted its position in Delcath Systems by 128.1% in the 2nd quarter. Geode Capital Management LLC now owns 703,171 shares of the company’s stock valued at $9,565,000 after purchasing an additional 394,902 shares during the last quarter. Nantahala Capital Management LLC acquired a new position in Delcath Systems during the 3rd quarter valued at about $7,164,000. Finally, Goldman Sachs Group Inc. boosted its stake in Delcath Systems by 116.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 587,678 shares of the company’s stock valued at $5,936,000 after purchasing an additional 315,583 shares during the period. 61.12% of the stock is owned by institutional investors and hedge funds.

Delcath Systems announced that its Board of Directors has approved a stock repurchase plan on Thursday, November 20th that permits the company to repurchase $25.00 million in outstanding shares. This repurchase authorization permits the company to reacquire up to 8.6% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

Key Delcath Systems News

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Publication of full CHOPIN randomized Phase 2 clinical trial results in The Lancet Oncology supports Delcath’s clinical credibility and could help commercial adoption and future partnerships or trials. CHOPIN Clinical Trial Publication
• Neutral Sentiment: Analyst coverage remains constructive on the long horizon: HC Wainwright keeps a “Buy” rating and a $30 price target, and also published bullish FY2029–FY2030 EPS projections (showing material upside several years out), which supports a positive long‑term thesis even as near‑term estimates were cut. MarketBeat DCTH Coverage
• Neutral Sentiment: Coverage piece argues fundamentals remain intact despite recent share weakness and notes near‑term pressure from patient starts and planned investments; useful context for investors weighing operational vs. sentiment drivers. Seeking Alpha Article
• Neutral Sentiment: Reported short interest data is unreliable/malformed in the filings (shows zeros/NaN); nothing actionable from the published short‑interest numbers as provided.
• Negative Sentiment: HC Wainwright sharply cut near‑term and medium‑term EPS estimates across Q1–Q4 2026 and FY2026–FY2028 (examples: FY2026 to ($0.86) from $0.58; FY2027 to $0.10 from $1.25; FY2028 to $1.13 from $1.77), signaling weaker near‑term profitability expectations and higher execution risk — a likely driver of today’s downward pressure on the share price. HC Wainwright Estimate Revisions

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.